Trending

Amgen

Teva slumps after Express Scripts funds migraine rivals in US

Teva slumps after Express Scripts funds migraine rivals in US

A major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in

X

Teva slumps after Express Scripts funds migraine rivals in US

https://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/

Lilly pushes into migraine market as Emgality approved in US

Lilly pushes into migraine market as Emgality approved in US

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group

X

Lilly pushes into migraine market as Emgality approved in US

https://pharmaphorum.com/news/lilly-pushes-into-migraine-market-as-emgality-approved-in-us/

FDA approves Teva’s migraine drug, decision due on Lilly’s rival

FDA approves Teva’s migraine drug, decision due on Lilly’s rival

The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns

X

FDA approves Teva’s migraine drug, decision due on Lilly’s rival

https://pharmaphorum.com/news/fda-approves-tevas-migraine-drug-decision-due-on-lillys-rival/

Balancing the sySTEM

Balancing the sySTEM

A group of pharma companies – Amgen, AstraZeneca and GlaxoSmithKline – have partnered with the UK government’s Equalities

X

Balancing the sySTEM

https://pharmaphorum.com/r-d/views-analysis-r-d/balancing-the-system/

Amgen/AZ’s phase 3 asthma biologic could get fast review

Amgen/AZ’s phase 3 asthma biologic could get fast review

Tezepelumab could be used in more patients than marketed IL-5 asthma drugs

X

Amgen/AZ’s phase 3 asthma biologic could get fast review

https://pharmaphorum.com/news/amgen-azs-phase-3-asthma-biologic-could-get-fast-review/

Breakthrough designation AstraZeneca’s severe asthma drug

Breakthrough designation AstraZeneca’s severe asthma drug

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after

X

Breakthrough designation AstraZeneca’s severe asthma drug

https://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/

Concerns over Teva migraine drug because of manufacturing issues

Concerns over Teva migraine drug because of manufacturing issues

There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the

X

Concerns over Teva migraine drug because of manufacturing issues

https://pharmaphorum.com/news/concerns-over-teva-migraine-drug-because-of-manufacturing-issues/

FDA approves second Neupogen biosimilar

FDA approves second Neupogen biosimilar

Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA

X

FDA approves second Neupogen biosimilar

https://pharmaphorum.com/news/fda-approves-second-neupogen-biosimilar/

Amgen and UCB re-file Evenity for US approval

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that

X

Amgen and UCB re-file Evenity for US approval

https://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com